Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility

References

• Banerjee, A., and Tsiatis, A. A. (2006), “Adaptive Two-Stage Designs in Phase II Clinical Trials,” Statistics in Medicine, 25, 3382–3395. DOI: 10.1002/sim.2501.
   PubMed Web of Science ®Google Scholar
• Bowden, J., and Trippa L. (2017), “Unbiased Estimation for Response Adaptive Clinical Trials,” Statistical Methods in Medical Research, 26, 2376–2388. DOI: 10.1177/0962280215597716.
   PubMed Web of Science ®Google Scholar
• Chen, Y. H., DeMets, D. L., and Lan, K. K. G. (2004), “Increasing the Sample Size When the Unblinded Interim Result Is Promising,” Statistics in Medicine, 23, 1023–1038. DOI: 10.1002/sim.1688.
   PubMed Web of Science ®Google Scholar
• Englert, S., and Kieser, M. (2012a), “Adaptive Designs for Single-Arm Phase II Trials in Oncology,” Pharmaceutical Statistics, 11, 241–249.
   PubMed Web of Science ®Google Scholar
• Englert, S., and Kieser, M. (2012b), “Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials,” Biometrics, 68, 886–892.
   PubMed Web of Science ®Google Scholar
• Fleming, T. R. (1982), “One-Sample Multiple Testing Procedure for Phase II Clinical Trials,” Biometrics, 38, 143–151.
   PubMed Web of Science ®Google Scholar
• Green, S. J., and Dahlberg, S. (1992), “Planned versus Attained Design in Phase II Clinical Trials,” Statistics in Medicine, 11, 853–862. DOI: 10.1002/sim.4780110703.
   PubMed Web of Science ®Google Scholar
• Koyama, T., and Chen, T. (2008), “Proper Inference from Simon’s Two-Stage Designs,” Statistics in Medicine, 27, 3145–3154.
   PubMed Web of Science ®Google Scholar
• Lee, J. J., and Liu, D. D. (2008), “A Predictive Probability Design for Phase II Cancer Clinical Trials,” Clinical Trials, 5, 93–106.
   PubMed Web of Science ®Google Scholar
• Leventhal, B. G., and Wittes, R. E. (1988), Research Methods in Clinical Oncology, New York: Raven Press.
   Google Scholar
• Li, G., Shih, W. J., Xie, T., and Lu, J. (2002), “A Sample Size Adjustment Procedure for Clinical Trials based on Conditional Power,” Biostatistics, 3, 277–287. DOI: 10.1093/biostatistics/3.2.277.
   PubMed Web of Science ®Google Scholar
• Lin, Y., and Shih, W. J. (2004), “Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials,” Biometrics, 60, 482–490. DOI: 10.1111/j.0006-341X.2004.00193.x.
   PubMed Web of Science ®Google Scholar
• Luo, X., Li, M., Shih, W. J., and Ouyang, P. (2012), “Estimation of Treatment Effect Following a Clinical Trial with Adaptive Design,” Journal of Biopharmaceutical Statistics, 22, 700–718. DOI: 10.1080/10543406.2012.676534.
   PubMed Web of Science ®Google Scholar
• Mehta, C. R., and Pocock, S. J. (2011), “Adaptive Increase in Sample Size When Interim Results are Promising: A Practical Guide with Examples,” Statistics in Medicine, 30, 3267–3284. DOI: 10.1002/sim.4102.
   PubMed Web of Science ®Google Scholar
• Muller, H. H., and Schafer, H. (2004), “A General Statistical Principle for Changing a Design Anytime during the Course of a Trial,” Statistics in Medicine, 23, 2497–2508.
   PubMed Web of Science ®Google Scholar
• NCT04761198. “A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE).” Available at https://www.clinicaltrials.gov/ct2/show/NCT04761198?term=NCT04761198/&draw=2/&rank=1
   Google Scholar
• NCT04913220. “A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers.” Available at https://www.clinicaltrials.gov/ct2/show/NCT04913220?term=NCT04913220/&draw=2/&rank=1
   Google Scholar
• Proschan, M. A., and Hunsberger, S. A. (1995), “Designed Extension of Studies based on Conditional Power,” Biometrics, 51, 1315–1324.
   PubMed Web of Science ®Google Scholar
• Scharfstein, D. O., Tsiatis, A. A., and Robins, J. M. (1997), “Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies,” Journal of the American Statistical Association, 92, 1342–1350.
   Web of Science ®Google Scholar
• Shih, W. J., Li, G., and Wang, Y. (2016), “Methods for Flexible Sample-Size Design in Clinical Trials: Likelihood, Weighted, Dual Test, and Promising Zone Approaches,” Contemporary Clinical Trials, 47, 40–48.
   PubMed Web of Science ®Google Scholar
• Simon, R. (1989), “Optimal Two-Stage Designs for Phase II Clinical Trials,” Controlled Clinical Trials, 10, 1–10. DOI: 10.1016/0197-2456(89)90015-9.
   PubMedGoogle Scholar
• Wang, Y., Li, G., and Shih, W. J. (2010), “Estimation and Confidence Intervals for Two-Stage Sample-Size-Flexible Design with LSW Likelihood Approach,” Statistics in Biosciences, 2, 180–190.
   Google Scholar
• Wu, Y., and Shih, W. J. (2008), “Approaches to Handling Data When a Phase II Trial Deviates from the Pre-specified Simon’s Two-Stage Design,” Statistics in Medicine, 27, 6190–6208.
   PubMed Web of Science ®Google Scholar
• Xie, T., Zhang, P., Shih, W. J., Tu, Y., and Lan, K. K. G. (2021), “Dynamic Monitoring of Ongoing Clinical Trials,” Statistics in Biopharmaceutical Research, 14, 580–591. DOI: 10.1080/19466315.2021.1880965.
   Web of Science ®Google Scholar